You are here

Phase III Study Evaluates Ramucirumab as Single Agent in Gastric Cancer

Second-line therapy improved survival (Oct. 15)

The phase III REGARD trial — a study of ramucirumab (IMC-1121B; Eli Lilly) in patients with metastatic gastric cancer — has met its primary endpoint of improved overall survival and also showed prolonged progression-free survival, according to a recent report.

The REGARD trial compared ramucirumab and best supportive care (BSC) with placebo and BSC as second-line treatment of metastatic gastric or gastroesophageal-junction adenocarcinoma following disease progression during first-line platinum- or fluoropyrimidine-containing combination therapy.

The primary endpoint of the study was overall survival. Secondary endpoints included progression-free survival; the proportion of participants who were progression-free at week 12; the proportion of participants with an objective response; the duration of response; and safety.

The most frequent adverse reaction occurring at a higher rate in the ramucirumab arm than in the placebo arm was hypertension (12%). Other adverse reactions occurring at a higher rate in the ramucirumab arm were diarrhea and headache.

Ramucirumab is a fully human IgG1 monoclonal antibody receptor antagonist designed to bind the extracellular domain of vascular endothelial growth factor (VEGF) receptor-2, thereby blocking the interaction of VEGF ligands (VEGF-A, VEGF-C, and VEGF-D) and inhibiting receptor activation. VEGF receptor-2 is considered a primary mediator of angiogenesis. When activated by VEGF ligands, VEGF receptor-2 promotes endothelial cell proliferation and survival, migration, and vascular permeability.

Source: Eli Lilly, October 15, 2012.

Recent Headlines

Citrus, Berries, Broccoli Reduce Risk of Cancer and CVD
Changes in Antibiotic Recommendations for Children
Influences Gene Involved in Circadian Rhythms
‘The Perfect Drug for Trauma-Focused Psychotherapy’
Triggers the Body’s Own Natural Blood Flow Regulation
Inrebic Reduces Symptoms by 50% in Some Patients
Novel Catheter-based Technology for Treating Acute Ischemic Stroke
Decision supported by data from more than 4,000 patients